drugset / Trial / NCT05158491
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
Phase 1/2
Unknown
63 enrolled
JenKem Technology Co., Ltd.
Peking University Cancer Hospital & Institute · collab
RandomizedSequentialSingle-blindTreatment
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
Timeline
- Start
- 2021-11-11
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | JK-1201I | Unknown | 180 mg/m2 | — |
| Comparator | JK-1201I | Unknown | 220 mg/m2 | — |
| Comparator | JK-1201I | Unknown | 260 mg/m2 | — |
| Comparator | JK-1201I | Unknown | 300 mg/m2 | — |